Huperzine-B

Pharmacology & Research

Huperzine B is a lycodine-type Lycopodium alkaloid from firmoss (Huperzia serrata) ^{10Reference 10Ma X et al. · 2007ReviewHuperzine A from Huperzia species — an ethnopharmacological reviewView study →} and the weaker, more selective sibling of the famous huperzine A. The honesty gate for the whole page: the human anti-Alzheimer/nootropic evidence — RCTs, meta-analyses and the negative independent US Phase II trial — belongs to huperzine A, not B. Huperzine B’s own literature is preclinical (Chinese pharmacology from 1987–2002 plus a few structural/in-vitro papers): it is a genuine reversible, AChE-selective cholinesterase inhibitor, roughly twice as weak as huperzine A but markedly more selective for AChE over butyrylcholinesterase.

1. Anti-Alzheimer / AChE inhibition

Huperzine B is a genuine reversible acetylcholinesterase inhibitor: it binds Torpedo AChE with a dissociation constant of ~0.33 µM (vs ~0.18 µM for huperzine A) at the same anionic subsite, triggering the same oxyanion-hole peptide flip ^{1Reference 1Dvir H et al. · 2002X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (−)-huperzine B: structural evidence for an active-site rearrangementView study →}; in mice it is highly AChE-over-BuChE selective (BuChE:AChE IC50 ratio ~66, vs 0.54 for tacrine) and less toxic than tacrine ^{2,3Reference 2Liu J et al. · 1999AnimalInhibitory effects of huperzine B on cholinesterase activity in miceView study →Reference 3Xu H · 1987Cholinesterase inhibition by huperzine BView study →}.

Gap: no human isolate trials for Alzheimer’s — all positive human dementia data are huperzine A — and the “wider therapeutic margin” is inferred from selectivity plus a tacrine (not huperzine A) toxicity comparison, not a therapeutic-index study ^{2Reference 2Liu J et al. · 1999AnimalInhibitory effects of huperzine B on cholinesterase activity in miceView study →}.

2. Memory / cognition

Two early Chinese behavioural studies found huperzine B improved impaired memory and facilitated learning/spatial-discrimination memory in mice ^{6,7Reference 6Zhu XD · 1988AnimalImprovement of impaired memory in mice by huperzine A and huperzine BView study →Reference 7Zhu XD · 1987AnimalFacilitatory effects of huperzine A and B on learning and memory of spatial discrimination in miceView study →}.

Gap: small, dated (1987–88), with no dose-response replication and no human data — direction-of-effect only, and huperzine B was consistently the weaker of the two alkaloids ^{6,7Reference 6Zhu XD · 1988AnimalImprovement of impaired memory in mice by huperzine A and huperzine BView study →Reference 7Zhu XD · 1987AnimalFacilitatory effects of huperzine A and B on learning and memory of spatial discrimination in miceView study →}.

3. Neuroprotection

Huperzine B attenuated H₂O₂-induced injury in PC12 cells (preserving glutathione peroxidase/catalase, lowering malondialdehyde) ^{4Reference 4Zhang HY · 2000Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen-peroxide-induced injury in PC12 cellsView study →} and protected them against oxygen-glucose-deprivation injury ^{5Reference 5Wang ZF et al. · 2002AnimalHuperzine B protects rat pheochromocytoma cells against oxygen-glucose-deprivation-induced injuryView study →}; a bis-huperzine-B derivative reproduced this against amyloid-β and apoptotic stress (supportive context only) ^{9Reference 9Wang ZF et al. · 2008Pharmacodynamic study of FS-0311, a novel highly potent, selective acetylcholinesterase inhibitor (a bis-huperzine-B derivative)View study →}.

Gap: in-vitro only, at micromolar concentrations far above plausible CNS exposure, and shared by all cholinesterase inhibitors tested — not huperzine-B-specific ^{4,5Reference 4Zhang HY · 2000Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen-peroxide-induced injury in PC12 cellsView study →Reference 5Wang ZF et al. · 2002AnimalHuperzine B protects rat pheochromocytoma cells against oxygen-glucose-deprivation-induced injuryView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Acetylcholinesterase (AChE)	reversible inhibition (Kd ~0.33 µM); anionic-subsite binding, oxyanion-hole flip	cognition, anti-AD
AChE-vs-BuChE selectivity	strongly AChE-selective (more so than tacrine)	safety margin / fewer peripheral effects
Oxidative-stress defence	↑ GSH-peroxidase, catalase, SOD; ↓ malondialdehyde (stressed PC12)	neuroprotection (in-vitro)
NMDA / glutamate; NGF / Nrf2 / APP	not established for huperzine B (documented for huperzine A only)	— (not attributed to B)

Pharmacokinetics

Huperzine B is a small, basic lycodine-type alkaloid, and its human pharmacokinetics are unknown — no isolate PK studies exist. In mice, a single oral dose produced steady-state brain AChE inhibition within ~4 h, indicating oral absorption and blood-brain-barrier penetration in rodents ^{2Reference 2Liu J et al. · 1999AnimalInhibitory effects of huperzine B on cholinesterase activity in miceView study →}; its half-life is not characterised for huperzine B (huperzine A’s ~5–14 h in humans should not be transferred to it). It is present at low levels in Huperzia serrata alongside huperzine A and is typically co-isolated by chromatography.

Clinical trials

There are no robust human clinical trials of isolated huperzine B for any indication. The dementia/cognition RCTs, meta-analyses and the negative US Phase II trial all concern huperzine A (see huperzine A) — no human efficacy should be presented for huperzine B.

Last checked: July 2026.

Toxicity & Safety

Huperzine B carries a provisional [low] flag — it is a genuinely active but weaker AChE inhibitor than huperzine A (~2× lower binding affinity), with markedly higher AChE-over-BuChE selectivity and lower toxicity than tacrine in mice ^{1,2Reference 1Dvir H et al. · 2002X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (−)-huperzine B: structural evidence for an active-site rearrangementView study →Reference 2Liu J et al. · 1999AnimalInhibitory effects of huperzine B on cholinesterase activity in miceView study →} — set one step below huperzine A’s [moderate]. Two caveats are built into the flag: it is not a benign nutrient — as a cholinesterase inhibitor it carries the class cholinergic side-effect ceiling (nausea, GI upset, sweating, bradycardia) at sufficient dose, and effects on skeletal muscle and the EEG were recorded in early rodent work ^{8Reference 8Yan XF et al. · 1987Effects of huperzine A and B on skeletal muscle and the electroencephalogramView study →}; and there is essentially no human isolate exposure data, so “low” reflects lower intrinsic potency plus selectivity, not a demonstrated human safety record. It should not be combined with other cholinesterase inhibitors or cholinergic drugs.

Pregnancy & lactation

Avoid. There are no reproductive or developmental data for huperzine B, and a centrally-penetrant cholinesterase inhibitor should not be assumed safe in pregnancy or lactation.

Dosage

There is no established human dose for isolated huperzine B — it is not sold as a standalone standardised supplement, occurring only as a minor co-alkaloid in Huperzia serrata extracts standardised to huperzine A. (The nootropic figure of ~50–200 µg/day belongs to the huperzine A page, not here.)

References